Cited 0 times in
Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, JE | - |
dc.contributor.author | Noh, OK | - |
dc.contributor.author | Lee, Y | - |
dc.contributor.author | Choi, HS | - |
dc.contributor.author | Han, JW | - |
dc.contributor.author | Hahn, SM | - |
dc.contributor.author | Lyu, CJ | - |
dc.contributor.author | Lee, JW | - |
dc.contributor.author | Yoo, KH | - |
dc.contributor.author | Koo, HH | - |
dc.contributor.author | Jeong, SY | - |
dc.contributor.author | Sung, KW | - |
dc.date.accessioned | 2022-12-07T05:53:27Z | - |
dc.date.available | 2022-12-07T05:53:27Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/23164 | - |
dc.description.abstract | PURPOSE: Loss of heterozygosity (LOH) at chromosomes 1p and 16q is a poor prognostic factor in favorable histology Wilms tumor (FHWT). This study investigated the prevalence of LOH at 1p and 16q and evaluated its prognostic value in Korean children with FHWT. MATERIALS AND METHODS: We analyzed 101 FHWT patients who were diagnosed between 1996 and 2016 in Korean Society of Pediatric Hematology Oncology Group hospitals. Using paraffin-embedded kidney tissue samples sent from each center, we reviewed LOH at 1p and 16q in each patient and assessed the prognostic value of LOH status for clinical parameters affecting event-free survival (EFS). RESULTS: Of the 101 patients, 12 (11.9%) experienced recurrence; the 3-year EFS was 87.6%. LOH at 1p or 16q was detected in 19 patients (18.8%), with five having LOH at both 1q and 16q. The frequency of LOH at 1p was higher among younger patients (p=0.049), but there was no difference in LOH prevalence according to tumor stage. In the multivariate analysis, LOH at 16q was a significant negative prognostic factor affecting EFS (3-year EFS, 73.7% vs. 91.1%; hazard ratio, 3.95; p=0.037), whereas LOH at 1p was not (p=0.786). CONCLUSION: LOH at 16q was a significant negative prognostic factor affecting outcome in Korean pediatric FHWT patients. Due to the small sample size of this study, large-scale multicenter trials are warranted to investigate the prognostic value of LOH at 1p and 16q in Korean children with FHWT. | - |
dc.language.iso | en | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Chromosomes, Human, Pair 16 | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Infant, Newborn | - |
dc.subject.MESH | Loss of Heterozygosity | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Wilms Tumor | - |
dc.title | Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG) | - |
dc.type | Article | - |
dc.identifier.pmid | 31505910 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176966 | - |
dc.subject.keyword | Wilms tumor | - |
dc.subject.keyword | Loss of heterozygosity | - |
dc.subject.keyword | 16q | - |
dc.subject.keyword | 1p | - |
dc.subject.keyword | Survival | - |
dc.subject.keyword | Prognosis | - |
dc.contributor.affiliatedAuthor | Park, JE | - |
dc.contributor.affiliatedAuthor | Noh, OK | - |
dc.contributor.affiliatedAuthor | Lee, Y | - |
dc.contributor.affiliatedAuthor | Jeong, SY | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.4143/crt.2019.313 | - |
dc.citation.title | Cancer research and treatment | - |
dc.citation.volume | 52 | - |
dc.citation.number | 2 | - |
dc.citation.date | 2020 | - |
dc.citation.startPage | 438 | - |
dc.citation.endPage | 445 | - |
dc.identifier.bibliographicCitation | Cancer research and treatment, 52(2). : 438-445, 2020 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalid | J015982998 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.